Is preemptive therapy for CMV infection following liver transplantation superior to symptom-triggered treatment?
Department of Surgery, Charite Campus Virchow, Berlin, Germany.
N
N
Rayes
D
D
Seehofer
C A
CA
Schmidt
A R
AR
Müller
T
T
Steinmüller
W O
WO
Bechstein
P
P
Neuhaus
D000284:Administration, Oral; D000956:Antigens, Viral / Q000097:blood; D000998:Antiviral Agents / Q000008:administration & dosage*; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D003586:Cytomegalovirus Infections / Q000188:drug therapy / Q000276:immunology / Q000517:prevention & control*; D005260:Female; D015774:Ganciclovir / Q000008:administration & dosage*; D006801:Humans; D016031:Liver Transplantation / Q000276:immunology; D008297:Male; D008875:Middle Aged; D010750:Phosphoproteins / Q000097:blood; D011446:Prospective Studies; D014763:Viral Matrix Proteins / Q000097:blood
D000956:Antigens, Viral; D000998:Antiviral Agents; D015415:Biomarkers; D010750:Phosphoproteins; D014763:Viral Matrix Proteins; C065418:cytomegalovirus matrix protein 65kDa; D015774:Ganciclovir